All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Report Forecasts Double-Digit Increase in Cancer Drug Spending

May 20th 2011

The amount of money spent in the United States on oncology drugs is expected to rise from 8% to 15% a year through 2013

FDA Grants Priority Review to Pfizer's Crizotinib

May 19th 2011

Crizotinib was accepted for filing by the FDA and granted Priority Review status

Towards Personalized Medicine in Ovarian Cancer

May 19th 2011

The goal of personalized medicine remains in its infancy as oncologists strive to determine treatments specific to a patient's tumor characteristics

Roche Files Vemurafenib for Regulatory Approval

May 17th 2011

Vemurafenib works by selectively targeting and inhibiting a mutated form of the BRAF protein found in about half of all cases of melanoma

New Information about Fatigue Experienced by Breast Cancer Survivors

May 16th 2011

Higher levels of norepinephrine are found in women with persistent fatigue.

ASTRO Issues Guidelines for Palliative Lung Cancer Care

May 13th 2011

ASTRO has for the first time issued its own extensive guidelines for the use of palliative thoracic radiotherapy in patients with metastatic lung cancer

Four-Drug Chemotherapy Combo Extends Lives of Patients with Pancreatic Cancer

May 12th 2011

Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma

Cancer Cells Outsmarting Smart Bombs: Gastrointestinal Stromal Tumors (GIST)

May 12th 2011

Certain patients whose cancer cells form mutations and build up a resistance to drugs, drive the need for second- and third-line therapies

Oncolytic Viruses Target Pancreatic Stem Cells

May 10th 2011

Oncolytic viruses have the potential of killing cancer stem cells, particularly in cases of potentially fatal pancreatic cancer

Osteosarcoma Survivor Sings Message of Hope

May 9th 2011

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States

Smoking Bans

May 9th 2011

Half of US states currently have anti-smoking laws; the goal is 100%

Revlimid Results for Multiple Myeloma Deemed "Historic"

May 6th 2011

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

FDA Approves Afinitor for Pancreatic Cancer

May 6th 2011

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease

Senators Introduce Bill to Correct Medicare Reimbursement for Cancer Drugs

May 5th 2011

Reimbursement is often insufficient to cover the purchase cost of cancer drugs, forcing oncologists to pay out of pocket to treat patients

Speculating Spectrum: More buzz about stock prices than the recently approved Fusilev indication

May 5th 2011

Spectrum Pharmaceuticals stock prices are the biggest story across the internet, not the FDA's approval of Fusilev

FDA Accepts BLA Filings for Lymphoma Treatments

May 3rd 2011

Seattle Genetics, Inc announced on Monday that the FDA has accepted filings for two Biologics License Applications for bretuximab vedotin

Ipilimumab's Unique Side Effects Require Unique Management

May 2nd 2011

Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals

Aflibercept Delivers Positive Results in Colorectal Trial

April 29th 2011

Aflibercept, an investigational angiogenesis inhibitor, improved overall survival as a second-line treatment for patients with mCRC

FDA Approves Abiraterone as Prostate Cancer Treatment

April 28th 2011

Abiraterone acetate gains FDA approval by demonstrating the ability to extend survival in patients with metastatic castrate-resistant prostate cancer

PARP Inhibitors May Help Fight Colon Cancer

April 28th 2011

A class of drugs that has shown encouraging results in breast and ovarian cancers with BRCA gene mutations may also benefit patients who have colorectal cancers